Lumosity

What Lumosity does

Lumosity (operating as Lumos Labs, Inc.) is a consumer cognitive training platform founded in 2005 and headquartered in San Francisco, offering over 40 brain training games organized across five core cognitive domains: memory, speed, attention, flexibility, and problem solving. The platform employs an adaptive algorithm that personalizes game difficulty based on individual user performance and tracks progress via a proprietary metric called the Lumosity Performance Index (LPI), translating 15+ years of cognitive science research into gamified training tasks adapted from laboratory psychology. The company has accumulated 120 million registered users globally across 20 years of operation, with the platform localized into seven languages (English, Spanish, French, German, Japanese, Korean, Portuguese). Cumulative private funding has totaled approximately $67.5 million across Series A through C rounds between 2007 and 2014.

The business operates a product-led, freemium go-to-market model with a free tier offering basic brain training and a paid premium subscription unlocking enhanced features, personalized training, and detailed analytics on a monthly billing cadence. Distribution is digital-first across the proprietary web platform (app.lumosity.com), iOS App Store, and Google Play, with no enterprise or B2B sales motion in the consumer business. Beyond the core product, Lumosity maintains sub-brands including Lumosity Mind (meditation), Figment (creativity), and LumiKids (pediatric cognitive training), each accessible as standalone mobile applications. Pricing is not publicly disclosed but operates on recurring subscription mechanics. Clinical validation of the platform is supported by a randomized 4,715-participant study published in a peer-reviewed journal, in which Lumosity users improved more than an active crossword-puzzle control group on working memory, short-term memory, processing speed, problem solving, fluid reasoning, and overall cognitive function after 10 weeks of 15-minute daily sessions.

In December 2025 the company received FDA 510(k) clearance for LumosityRx, a prescription digital therapeutic for adults with ADHD that demonstrated statistically significant improvements in attention measures and quality of life in a randomized controlled clinical trial of over 500 participants, with high adherence and minimal adverse effects. This regulatory milestone represents Lumosity's strategic extension from a consumer brain-training app into the prescription digital therapeutics channel, where distribution is healthcare-provider-driven and revenue mechanics shift to reimbursement-based pricing rather than monthly consumer subscriptions. The move opens the $1.9 billion global ADHD apps market projected to reach $6.7 billion by 2033, although commercial adoption at inception is minimal given the late-2025 clearance timing.

Name

Lumosity

Legal name

Lumos Labs, Inc.

Website

https://lumosity.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

Lumosity operates an adaptive brain training platform serving 120 million registered users across five cognitive domains via freemium and premium subscriptions. The company holds FDA 510(k) clearance for LumosityRx, a prescription digital therapeutic for adults with ADHD.

Ownership category

akta.pro rank

Product category

Cognitive Training Software

NAICS

Software Publishers (513210), Educational Support Services (611710)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Intelligent Practice & Mastery Learning Platforms (Spaced Repetition, Skill Drills) (EDAFAFAD)

akta.pro secondary industry

Executive Functioning & Behavioral Support Tools (ADHD, SEL/Behavior Tracking, Routines) (EDAFAKAG)

Keywords

• Cognitive training software
• Brain training games
• Digital therapeutics
• Prescription digital therapeutics
• Neuropsychology assessments

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Subscription Revenue: Lumosity operates primarily on a subscription model where users pay for premium access to enhanced features, personalized training programs, and detailed analytics. The platform offers both free basic access and paid premium subscriptions.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Lumosity provides an online cognitive training platform featuring 40+ brain games that target memory, attention, problem-solving, processing speed, and mental flexibility. The platform uses an adaptive algorithm that personalizes difficulty based on individual performance and tracks progress through the proprietary Lumosity Performance Index (LPI). In addition to the consumer-facing app, the company offers LumosityRx, an FDA 510(k)-cleared prescription digital therapeutic for adults with ADHD demonstrated through clinical trials with over 500 participants.

Product overview

Lumosity is a cognitive training platform developed by Lumos Labs offering a suite of brain training products. The core offering is the Lumosity app with over 40 cognitive games organized into categories: Memory, Speed, Attention, Flexibility, Problem Solving, Math, and Word games. The platform adapts to each user's unique cognitive profile using an adaptive algorithm. Additional products include LumosityRx (FDA-cleared prescription digital therapeutic for ADHD), Lumosity Mind (meditation app), Figment (creativity app), and LumiKids (child-focused cognitive training). The company has served over 100 million users across 20 years of operation with products available in 7 languages.

Differentiator

Problem solved

Functional benefit

Brands

• LumosityRx: Prescription digital therapeutic for adults with ADHD, cleared by FDA in December 2025
• Lumosity Mind
• Figment
• LumiKids

Products and services

• Lumosity (Core App) Primary brain training platform offering over 40 cognitive games designed to exercise memory, attention, problem-solving, processing speed, and mental flexibility. Features personalized daily workouts, adaptive difficulty, and progress tracking via the Lumosity Performance Index (LPI). Targeted at individual consumers seeking daily brain training exercises.
• LumosityRx FDA 510(k)-cleared prescription digital therapeutic for adults with ADHD that demonstrated statistically significant improvements in attention measures and quality of life in controlled clinical trials. Distributed via prescription through healthcare providers.
• Lumosity Mind Meditation and mindfulness app available on iOS and Android platforms, complementing the brain training offerings for users seeking relaxation and mental wellness tools.
• Figment A creativity-focused brain training app by Lumosity available on iOS and Android, targeting users interested in creative thinking exercises.
• LumiKids Child-focused app designed to enhance early cognitive and social-emotional skills in young users through age-appropriate interactive games.

Quantifiable outcome

• Lumosity users improved more than control group on assessments of working memory, short-term memory, processing speed, problem solving, fluid reasoning, and overall cognitive function after 10 weeks (5 days/week, 15 min/day)
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• CogniFit: CogniFit offers personalized cognitive training apps and assessments for both consumers and clinical/researchers (including ADHD and special-needs populations), overlapping with both Lumosity's core product and LumiKids/LumosityRx clinical positioning.
• Akili Interactive: Akili's EndeavorRx is an FDA-cleared prescription video-game digital therapeutic (initially for pediatric ADHD) — making it the closest direct peer to LumosityRx in the cognitive-training-as-DTx category, and a category analog for Lumosity's consumer-plus-clinical dual model.
• Peak (Brain Training): Peak (by Brainbow) offers a direct-to-consumer brain-training app with categorized cognitive games (memory, attention, language, problem solving) developed with Cambridge neuroscientists — same product category, similar scientific positioning.
• Elevate: Elevate is a direct competitor to Lumosity's core app: a mobile brain-training subscription product covering memory, attention, and processing speed with daily adaptive workouts for adults.
• NeuroNation: NeuroNation is a science-based brain-training platform with personalized adaptive exercises across multiple cognitive domains, available globally with a freemium subscription model directly comparable to Lumosity.
• Posit Science (BrainHQ): BrainHQ/Posit Science provides scientifically validated computerized cognitive training (auditory/visual processing speed, memory) with clinical-research depth comparable to Lumosity's 15+ years of cognitive research backing.

Broad incumbents

• Calm: Calm is a dominant consumer mental-health/mindfulness subscription that competes with Lumosity Mind for the same wellness-oriented subscriber across overlapping demographics.
• Headspace: Headspace is a broader mental-wellness incumbent whose meditation/mindfulness subscription overlaps directly with Lumosity Mind and competes for the same consumer mental-fitness wallet share.

Emerging players

• Click Therapeutics: Click Therapeutics develops prescription digital therapeutics (including for ADHD) with FDA engagement — comparable to LumosityRx as a next-generation DTx competitor pursuing similar regulatory and payer pathways.
• Big Health: Big Health produces FDA-cleared prescription digital therapeutics (e.g., SleepioRx) for behavioral health — a peer category analog to LumosityRx as another clinical-grade DTx advancing into payer-covered prescription channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks4 records

Key highlights6 records

Customer concentration

• Xx.com/Lumosity
• Facebookfacebook.com/Lumosity
• LinkedInlinkedin.com/company/lumos-labs-lumosity-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumosity